Novel strategy in the treatment of liver metastases - Hepatic resection combined with stereotactic body radiotherapy
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31911035
DOI
10.1016/j.asjsur.2019.11.016
PII: S1015-9584(19)30861-9
Knihovny.cz E-zdroje
- Klíčová slova
- Colorectal liver metastases, Combined strategy, CyberKnife, Liver resection, Oligometastases, Stereotactic body radiotherapy, Survival,
- MeSH
- hepatektomie metody MeSH
- karcinom mortalita sekundární chirurgie MeSH
- kohortové studie MeSH
- kolorektální nádory patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory jater mortalita sekundární chirurgie MeSH
- pooperační komplikace epidemiologie MeSH
- radiochirurgie metody MeSH
- retrospektivní studie MeSH
- senioři MeSH
- studie proveditelnosti MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: To evaluate the safety, feasibility and outcomes of patients treated for colorectal liver metastases (CLM) with an innovative combined approach - hepatic resection and Stereotactic body radiotherapy (SBRT) using CyberKnife® system. METHODS: This was a retrospective cohort study conducted in a single institution. Patients with CLM and no evidence of extrahepatic disease were included during a 6-year study period. RESULTS: In total, 19 patients with 63 liver lesions underwent liver resection combined with SBRT of unresectable lesions. Major hepatectomy was performed in 42.1% patients; postoperative complications were noted in 31.6% patients. 27 unresectable lesions were treated by SBRT with a total dose of 50-60 Gy in five fractions. The median follow-up of study patients was 29.7 ± 20.58 months. Local control of CLM at 1 and 2 years was achieved in 89.5% of patients. Out-of-field hepatic recurrence was diagnosed in 63.1% patients. The 1-year disease-free survival (DFS) was 52.6%; 2-year DFS was 31.6%. The overall actuarial survival rates at 1 and 2 years were 88.2% and 50.4%. CONCLUSION: Liver resection combined with SBRT presents a promising therapeutic option for patients with CLM which traditionally are unresectable. The additional use of SBRT allows for the effective clearance of the disease for thoroughly selected patients.
Department of Oncology University Hospital Ostrava 17 listopadu 1790 Ostrava 708 52 Czech Republic
Department of Radiology University Hospital Ostrava 17 listopadu 1790 Ostrava 708 52 Czech Republic
Citace poskytuje Crossref.org
